Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What You Need To Know Ahead of Humana's Earnings Release

Valued at a market cap of $23.7 billion, Humana Inc. (HUM) is a U.S.-based healthcare company that provides medical and specialty insurance products through its Insurance and CenterWell segments, serving individuals, Medicare beneficiaries, and military families. It also operates senior-focused primary care centers, home health services, and pharmacy solutions.

The Louisville, Kentucky-based company is slated to announce its fiscal Q1 2026 results before the market opens on Wednesday, Apr. 29. Ahead of the event, analysts forecast Humana to report an adjusted EPS of $9.89, down 14.6% from $11.58 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates...

Fundamentals

See More
  • Market Capitalization, $K 177,352,944
  • Shares Outstanding, K 1,741,657
  • Annual Sales, $ 44,328 M
  • Annual Income, $ 6,524 M
  • EBIT $ 9,735 M
  • EBITDA $ 12,851 M
  • 60-Month Beta 0.79
  • Price/Sales 4.02
  • Price/Cash Flow 14.72
  • Price/Book 3.39

Options Overview Details

View History
  • Implied Volatility 30.50% (-1.71%)
  • Historical Volatility 19.33%
  • IV Percentile 93%
  • IV Rank 64.81%
  • IV High 37.85% on 04/10/25
  • IV Low 16.97% on 08/12/25
  • Expected Move (DTE 2) 1.70 (1.64%)
  • Put/Call Vol Ratio 0.52
  • Today's Volume 2,185
  • Volume Avg (30-Day) 10,953
  • Put/Call OI Ratio 0.95
  • Today's Open Interest 149,130
  • Open Int (30-Day) 155,702
  • Expected Range 101.66 to 105.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.14
  • Number of Estimates 9
  • High Estimate $1.17
  • Low Estimate $1.13
  • Prior Year $1.09
  • Growth Rate Est. (year over year) +4.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.88 +2.64%
on 03/31/26
112.74 -8.16%
on 03/09/26
-6.02 (-5.49%)
since 03/06/26
3-Month
100.88 +2.64%
on 03/31/26
127.14 -18.56%
on 01/09/26
-22.64 (-17.94%)
since 01/08/26
52-Week
100.88 +2.64%
on 03/31/26
139.06 -25.54%
on 06/24/25
-20.41 (-16.47%)
since 04/08/25

Most Recent Stories

More News
What You Need To Know Ahead of Humana's Earnings Release

Humana is scheduled to release its first-quarter results later this month, with analysts projecting double-digit earnings drop.

HUM : 198.74 (+0.81%)
ABT : 103.29 (+1.43%)
XLV : 149.20 (+1.79%)
$SPX : 6,773.92 (+2.37%)
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?

Abbott Laboratories' recent stock price dip contrasts with its strong Medical Devices division, creating a noteworthy opportunity for dividend investors.

ABT : 103.29 (+1.43%)
Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

ABT : 103.29 (+1.43%)
JNJ : 240.01 (+0.67%)
1 Healthcare Stock on Our Watchlist and 2 We Find Risky

1 Healthcare Stock on Our Watchlist and 2 We Find Risky

ABT : 103.29 (+1.43%)
AORT : 35.99 (+2.19%)
QDEL : 15.70 (+4.81%)
Buy the Dip: These 3 Over-$100 Stocks Just Hit New 52-Week Lows

Among the 128 new 52-week lows on the NYSE on Tuesday, there were five with share prices of $100 or higher. Not all of them are worth buying on the dip. We rate three that could be.

ABT : 103.29 (+1.43%)
PGR : 197.37 (+0.26%)
AVB : 168.17 (+0.26%)
This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion,...

ABT : 103.29 (+1.43%)
JNJ : 240.01 (+0.67%)
MDT : 88.36 (+2.24%)
$INX : 6,774.84 (+2.39%)
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

ABBOTT PARK, Ill. and NEW YORK , March 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions...

ABT : 103.29 (+1.43%)
Abbott hosts conference call for first-quarter earnings

ABBOTT PARK, Ill. , March 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens.

ABT : 103.29 (+1.43%)
Abbott Earnings Preview: What to Expect

Abbott is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

ABT : 103.29 (+1.43%)
XLV : 149.20 (+1.79%)
$SPX : 6,773.92 (+2.37%)
John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

ABBOTT PARK, Ill. , March 24, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer. The company...

ABT : 103.29 (+1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures...

See More

Key Turning Points

3rd Resistance Point 104.06
2nd Resistance Point 103.46
1st Resistance Point 102.65
Last Price 103.29
1st Support Level 101.23
2nd Support Level 100.63
3rd Support Level 99.82

See More

52-Week High 139.06
Fibonacci 61.8% 124.47
Fibonacci 50% 119.97
Fibonacci 38.2% 115.46
Last Price 103.29
52-Week Low 100.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.